14C BMS-275183
Term · Oncology and biomedicine · MLC-T-ONC-009516
An orally bioavailable taxane compound, a C-4 methyl carbonate analogue of paclitaxel, labeled with radioactive carbon 14, with potential antineoplastic and radioimaging activities. BMS-275183 binds to tubulin and as a result inhibits microtubule disassembly or assembly. This leads to cell cycle arrest at the G2/M phase, thereby resulting in an inhibition of cell division and ultimately cell death. BMS-275183 may be useful for treating multi-drug resistant tumors as it does not appear to be a substrate for P-glycoprotein.
| Identifier | MLC-T-ONC-009516 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | [14C] BMS-275183 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-009516",
"term": "14C BMS-275183",
"field": "Oncology and biomedicine",
"definition": "An orally bioavailable taxane compound, a C-4 methyl carbonate analogue of paclitaxel, labeled with radioactive carbon 14, with potential antineoplastic and radioimaging activities. BMS-275183 binds to tubulin and as a result inhibits microtubule disassembly or assembly. This leads to cell cycle arrest at the G2/M phase, thereby resulting in an inhibition of cell division and ultimately cell death. BMS-275183 may be useful for treating multi-drug resistant tumors as it does not appear to be a substrate for P-glycoprotein.",
"synonyms": [
"[14C] BMS-275183"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/14c-bms-275183/"
}
Record 19 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.